Investors Face August Deadline in Securities Suit Against Erasca

The lawsuit, Cheng v. Erasca, Inc., alleges that the company and its top executives violated the Securities Exchange Act of 1934 by issuing false statements about the development of ERAS-0015, a molecular glue designed to treat RAS-mutated solid tumors. According to the complaint, the company’s preclinical data relied on improper comparisons to Revolution Medicines, Inc., potentially exposing Erasca to patent and trade secret infringement claims.

Market confidence faltered following two major disclosures in late April 2026. On April 27, Erasca revealed a patent infringement warning from Revolution Medicines, causing an 11% drop in share price. Later that day, the company disclosed preliminary Phase I clinical data, which included the death of a patient and an admission that previous performance comparisons were not based on head-to-head clinical trials. Shares subsequently plummeted more than 48%. Investors seeking to serve as lead plaintiff in the case, represented by Robbins Geller Rudman & Dowd LLP, must meet the court's requirements for financial interest and adequacy.